FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults

Galcanezumab is the first of three investigational, non-opioid treatments in Lilly's pain portfolio

INDIANAPOLIS, Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug A... Biopharmaceuticals, FDA Eli Lilly, Galcanezumab, migraine

Source: HSMN NewsFeed - December 11, 2017 Category: Pharmaceuticals Source Type: news